APA   Click to copy
D'Angelo, A., Sobhani, N., Chapman, R., Bagby, S., Bortoletti, C., Traversini, M., … Roviello, G. (2020). Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers, 12(11), 3293. https://doi.org/10.3390/cancers12113293

Chicago/Turabian   Click to copy
D'Angelo, Alberto, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, and Giandomenico Roviello. “Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.” Cancers 12, no. 11 (2020): 3293.

MLA   Click to copy
D'Angelo, Alberto, et al. “Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.” Cancers, vol. 12, no. 11, 2020, p. 3293, doi:10.3390/cancers12113293.

@article{alberto2020a,
  title = {Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies},
  year = {2020},
  issue = {11},
  journal = {Cancers},
  pages = {3293},
  volume = {12},
  doi = {10.3390/cancers12113293},
  author = {D'Angelo, Alberto and Sobhani, Navid and Chapman, Robert and Bagby, Stefan and Bortoletti, Carlotta and Traversini, Mirko and Ferrari, Katia and Voltolini, Luca and Darlow, Jacob and Roviello, Giandomenico}
}